EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|September 1, 2003
Kasabach-Merritt Phenomenon
Author(s)Barbara J. Rutledge, Ph.D.
San Francisco - It is important to go back to the literature to study the rare phenomenon known as Kasabach-Merritt phenomenon and review the published reports in light of what we currently know about vascular tumors, according to Beth A. Drolet, M.D. "Most of these lesions do involve the skin, so we as dermatologists can play a big part in diagnosis," said Dr. Drolet, associate professor of dermatology and pediatrics, Medical College of Wisconsin.
Advertisement
Advertisement
Related to this article
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5